KDIGO 2021肾小球疾病管理指南执行摘要
KDIGO 2021肾小球疾病管理指南是对2012版的更新,旨在帮助临床医生管理成人和儿童肾小球肾炎患者。该指南涵盖IgA肾病、膜性肾病、肾病综合征、微小病变、局灶节段性肾小球硬化、感染相关性肾小球肾炎、ANCA血管炎、狼疮肾炎、抗GBM病及补体介导疾病等,提供诊断、预后、治疗建议并指出研究空白。
要点
- 指南基于系统评价和GRADE方法制定,提供可操作推荐。
- 涵盖多种肾小球疾病,包括IgA肾病、膜性肾病、狼疮肾炎等。
- 首次纳入补体介导疾病亚型,并强调特殊情况和研究建议。
核心结论
- 指南为肾小球疾病管理提供基于证据的推荐,覆盖诊断、预后和治疗。
研究设计与样本
- KDIGO临床实践指南更新,基于系统评价和GRADE方法制定,目标人群为成人和儿童肾小球肾炎患者。
临床怎么用
- 临床医生可参考指南进行肾小球疾病的诊断、预后评估和治疗决策。
局限性
- 证据存在局限性,指南指出了未来研究的方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (GN), both adults and children. The scope includes various glomerular diseases, including IgA nephropathy and IgA vasculitis, membranous nephropathy, nephrotic syndrome, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), infection-related GN, antineutrophil cytoplasmic antibody (ANCA) vasculitis, lupus nephritis, and anti-glomerular basement membrane antibody GN. In addition, this guideline will be the first to address the subtype of complement-mediated diseases. Each chapter follows the same format providing guidance related to diagnosis, prognosis, treatment, and special situations. The goal of the guideline is to generate a useful resource for clinicians and patients by providing actionable recommendations based on evidence syntheses, with useful infographics incorporating views from experts in the field. Another aim is to propose research recommendations for areas where there are gaps in knowledge. The guideline targets a broad global audience of clinicians treating GN while being mindful of implications for policy and cost. Development of this guideline update followed an explicit process whereby treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed, with areas of future research also presented.
引用
- Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021. PMID: 34556300. doi:10.1016/j.kint.2021.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。